Section
A large-scale cross-sectional study of 51,202 admissions reveals that 35.6% of patients aged 70 and older experience cognitive morbidity, predominantly delirium. The findings underscore the urgent necessity for hospital-wide screening and m
A 36-week observational study demonstrates that subcutaneous lidocaine-HP-β-CD significantly improves physical and mental quality of life and reduces symptom burden in patients with post-COVID condition, offering a scalable, home-based ther
A hemodynamic study of 227 HFpEF patients reveals that 34% exhibit a low-output phenotype. This cold status, especially when combined with congestion, significantly increases mortality risk in overweight and obese individuals, highlighting
A recent systematic review and meta-analysis of 13 randomized controlled trials concludes that melatonin fails to reduce the incidence of delirium or mortality in critically ill patients, challenging the routine use of this supplement in th
The DEMEL trial found that while 0.3 mg of melatonin achieved a superior pharmacokinetic profile over 3 mg, it failed to reduce delirium incidence or improve clinical outcomes in mechanically ventilated patients compared to placebo.
A post-hoc analysis of the SEPSIS-PAM trial reveals that while high MAP targets do not provide a universal survival benefit, they significantly increase mortality risk when requiring high norepinephrine doses or failing to resolve microcirc
Recent large-scale studies, including HEART-FID and major national registries, demonstrate that transferrin saturation (TSAT) and serum iron levels are more accurate predictors of functional capacity and mortality in heart failure than trad
A pooled analysis of 21,479 HFpEF/HFmrEF patients reveals that waist-to-height ratio is a superior, linear predictor of mortality and heart failure events compared to BMI. Even in non-obese BMI categories, nearly 90% of patients exhibit exc
A pooled analysis of 14,750 patients reveals that current fixed NT-proBNP thresholds significantly underestimate cardiovascular risk in obese patients with heart failure, suggesting a critical need for BMI-adjusted diagnostic and trial elig
A prespecified analysis of the FOURIER trial reveals that patients with obesity and atherosclerotic cardiovascular disease experience significantly higher absolute and relative risk reductions with evolocumab, particularly those with a BMI
Blarcamesine shows potential in slowing early Alzheimer’s progression, but questions about trial data robustness and transparency have been raised.
A groundbreaking study identifies N-palmitoyl glutamine (NPG) as a key molecular transducer of cardiorespiratory fitness. NPG correlates with VO2max, increases with exercise training, predicts lower mortality, and directly enhances mitochon
A secondary analysis of the ODYSSEY OUTCOMES trial reveals that oxidized phospholipids on apolipoprotein B-100 (OxPL-apoB) independently predict cardiovascular risk in ACS patients, particularly when Lp(a) levels are low. Treatment with ali
Recent findings from the ARIC study reveal that integrating cardiac biomarkers and echocardiography with the PREVENT-HF score significantly enhances the prediction of incident heart failure, identifying high-risk individuals who traditional
This review synthesizes evidence on tailored weight loss programs for adults with serious mental illness, highlighting recent advances, effectiveness, mechanistic insights, and future directions.
This review synthesizes evidence from a 2025 randomized clinical trial evaluating a tailored weight loss program, CoachToFit, for veterans with serious mental illness, highlighting its potential to improve weight outcomes via remote support
Recent Mendelian randomization analyses demonstrate causal effects of increased BMI and inflammatory bowel disease on hidradenitis suppurativa risk, elucidating modifiable contributions beyond genetic correlations with psoriasis and systemi
A longitudinal study from the Dallas Heart Study identifies calprotectin as a significant, independent predictor of ASCVD events, linking neutrophil activation to endothelial dysfunction and increased cardiovascular risk across diverse popu
This secondary analysis of the CONNECT trial demonstrates that achieving guideline-endorsed LDL-C levels significantly lowers the risk of neoatherosclerosis three years post-DES implantation in STEMI patients, underscoring the vital role of
A large-scale study from the Penn Medicine BioBank demonstrates that polygenic risk scores for hypertrophic and dilated cardiomyopathies act as bidirectional modifiers, influencing the clinical expression of rare pathogenic variants and off
